كاربرد قطره آديپونكتين در مقايسه با قطره بواسيزوماب در بهبود نورگ‌زايي قرنيه

Adiponectin versus Bevacizumab in Decreasing Corneal Neovascularization

هدف: مقايسه اثر آديپونكتين (Adiponectin) با بواسيزوماب(Bevacizumab) در كاهش نورگ‌زايي قرنيه. روش پژوهش: اين مطالعه بر روي 40 چشم از 20 خرگوش نر آلبينو نيوزيلندي صورت گرفت. القاي نورگ‌زايي قرنيه به وسيله يك بخيه سيلك 0-7 به طول 2 ميلي‌متر و به فاصله 1 ميلي‌متر از ليمبوس انجام شد. خرگوش‌ها به طور تصادفي به دو گروه ده‌تايي تقسيم شدند. براي چشم راست هر دو گروه از قطره آديپونكتين و براي چشم چپ، در گروه اول قطره اشك مصنوعي و گروه دوم قطره بواسيزوماب استفاده شد. اين درمان تا 14 روز ادامه يافت و خرگوش‌ها به طور منظم پي‌گيري شدند. در هر معاينه، تصويربرداري ديجيتال قرنيه صورت گرفت و پيشروي عروق به داخل قرنيه از لحاظ طول و سطح، اندازه‌گيري شد. يافته‌ها: در پايان 14 روز، طول پيشروي عروق در خرگوش‌هاي درمان شده با آديپونكتين از 0/32±2/123 ميلي‌متر (قبل از درمان) به 0/458±0/887 ميلي‌متر (بعد از درمان) كاهش يافت كه معادل 19/98±57/68 درصد (0/51±1/24 ميلي‌متر) كاهش بود (0/001

Purpose: To compare the effect of adiponectin versus bevacizumab on reducing corneal neovascularization Methods: This study was performed on 40 eyes of 20 New Zealand Albino male rabbits. Corneal neovascularization was induced by a 7-0 silk suture 2mm long and 1 mm away from the limbus. Rabbits were randomly divided into two groups of ten. In the first group, adiponectin eye drop and artificial tears were administered in the right and left eyes, respectively. In the second group, adiponectin eye drop was applied in the right eye and bevacizumab eye drop was used in the left eye for 14 days. The rabbits were examined regularly. Imaging was performed at each visit. The area of corneal vascularization and the length of vessels were measured and compared. Results: At the end of 14 days, the average length of vessels in the rabbits treated with adiponectin decreased from 2.12 ± 0.32 mm to 0.89 ± 0.46 mm, (57.68 ± 19.98% decrease ;1.24 ± 0.51mm) (P<0.001). The length of vessels were decreased by 57.68% ± 19.98% and 42.49% ± 27.17% in the adiponectin and bevacizumab groups, respectively (P= 0.527). At the end of 14 days, the average surface area of vessels in the rabbits treated with adiponectin reduced from 5.02±1.50 mm2 to 1.40 ±0.75 mm2 (%70.64± 17.76 decrease; 3.63±1.57 mm2) (P<0.001) . The mean surface area of vascularization was decreased by 70.64% ±17.76% and 48.24% ±19.23% in the adiponectin versus bevacizumab group, respectively (P= 0.013). Conclusion: The results of this study suggest that adiponectin can potentially decrease youn corneal neovascularization. Its effect seems to be at least comparable to bevacizumab.